Announcement on Authorizing the Chairman of the Company to Use Its Own Funds for Entrusted Financial Management
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 Number: Pro 2019-012
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Authorizing the Chairman of the Company to Use Its Own Funds to Entrust Financial Management
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Important Content Reminder:
● Entrusted Wealth Management Amount: Authorizes the Chairman of the Board to exercise the decision-making power of entrusted wealth management not exceeding RMB billion, within which funds can be used on a rolling basis, however, the total entrusted financial balance of surviving at any point in time shall not exceed 5 .4 billion yuan.
● Entrusted Wealth Management Investment Type: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
● Entrusted financial management period: the period of each investment business shall not exceed 12 months.
1. overview
(I) basic situation
1 , principle: take "standard operation, risk prevention, prudent investment, value preservation and appreciation" as the principle.
2 , Varieties: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
3 . Funds: own funds.
4 , authorized amount and term: the chairman of the board of directors is authorized to exercise the decision-making power of entrusted financial management not exceeding RMB 5 .3 billion yuan. within the amount, the funds can be used on a rolling basis, but the total balance of entrusted financial management existing at any time point shall not exceed RMB 5 .5 billion yuan. The term of each entrusted financial management shall not exceed 12 months. The authorization period shall be valid for 3 years from the date of approval by the Board of Directors of the Company. The specific investment activities are organized and implemented by the Company's Finance Department.
5 , Implementation Method: Authorize the chairman of the board to decide on matters related to entrusted financial investment within the above amount, including but not limited to: selecting qualified professional financial institutions, selecting specific types of entrusted financial products, specifying the amount and term of entrusted financial management, signing relevant contracts and agreements, etc.
(II) the approval procedures to be performed within the company
2019 , Zhejiang Jianfeng Group Co., Ltd. held the 106 meeting of the 10th board of directors, of which eight directors attended the meeting in person, director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting and vote on on his behalf. complies with the relevant provisions of the "Company Law" and the company's "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, with 9 votes in favor, 0 votes against, and 0 abstentions, the "Proposal on Authorizing the Chairman of the Company to Use Its Own Funds for Entrusted Financial Management " was deliberated and passed.
2. Main Contents
(I) Entrusted Funds Source: Own Funds .
Impact of (II) on the Company
1 . The entrusted financial management of the Company is implemented on the premise of ensuring the daily operation and capital safety of the Company, and does not affect the daily capital turnover of the Company or the normal development of the Company's business.
2 . Through moderate and low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.
(III) Risk Control Analysis
Company strictly follows the approval and implementation procedures of "Entrusted Financial Management System" to ensure the effective development and standardized operation of entrusted financial management and other investment businesses. However, as the financial market is greatly affected by the economic environment, it is not ruled out that investment businesses such as investment and wealth management will be affected by market fluctuations. The company will take the following measures:
( 1 ) The company will clearly assign special personnel to be responsible for the relevant work of such investment matters: the chairman of the company exercises the investment decision-making power and signs relevant contract documents, the company's financial director is responsible for organizing the implementation, and the finance department is responsible for the specific operation.
( 2 ) The company's finance department is responsible for timely analyzing and tracking the investment direction of financial products and the progress of investment projects. If the evaluation finds that there are conditions that may affect the company's capital security or affect the normal capital flow demand, corresponding preservation or redemption measures will be taken in time to control investment risks.
( 3 ) The audit department of the company is responsible for auditing and supervising various investments, and regularly auditing and verifying the progress, profit and loss, and risk control of entrusted financial management. According to the principle of prudence, evaluate the possible risks and benefits of various entrusted financial management and report to the audit committee of the board of directors.
( 4 ) The company fulfills its information disclosure obligations in strict accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.
(IV) Independent Director Opinion
The independent director of the company issued an independent opinion on the resolution, and believed that: the company's entrusted financial management is implemented on the premise of ensuring the company's daily operation and capital safety. It does not affect the company's daily capital turnover and does not affect the normal development of the company's business operations. By carrying out moderate low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.# The 174 has not found any damage to the rights and interests of the company and small and medium-sized shareholders. Agree to authorize the chairman to use his own funds for entrusted financial management.
"Announcement on the Progress of Entrusted Financial Management" on 2019 . As of the date of this announcement, the company has recovered all the entrusted financial management due.
As of the date of this announcement, the company's accumulated amount of entrusted financial management is 2.5 .4 billion yuan. See the following table for details:
| Trustee
| Financial Product Type
| Amount
(RMB 10,000)
| Start Date
| Due Date
|
Deadline Announcement Date recovered principal amount (RMB 10,000)
|
income as of the announcement date (RMB 10,000)
|
| 1
| Bank of Communications Jinhua Branch
|
Yuntong Wealth Fixed Term Structured Deposit
|
3,000.00
|
2019/2/1
|
2019/6/6
|
/
|
/
|
| 2
| Guangfa Bank Jinhua Branch
|
Salary Increase 16 RMB structured deposit product
|
5,000.00
|
2019/2/20
|
2019/5/21
|
/
|
/
|
|
Agricultural Bank of China Jinhua Jiangbei Sub-branch
|
Huili Feng 2019 4505 Issue Customized RMB Structured Deposit Product
|
5,000.00
|
2019/2/22
|
2019/5/24
|
/
|
/
|
4
|
Guangfa Bank Jinhua Branch
|
Salary Increase 16 RMB Structured Deposit Product
|
4,000.00
|
2019/4/9
|
2019/7/8
|
/
|
/
|
5
|
Bohai Bank Jinhua Branch
|
Bank Bohai S190534 Structured Deposit Financial Product
|
4,000.00
|
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page